Duroferon 100 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

duroferon 100 mg depottabletter

2care4 aps - ferrosulfat, tørret - depottabletter - 100 mg

Duroferon 100 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

duroferon 100 mg depottabletter

orifarm a/s - ferrosulfat, tørret - depottabletter - 100 mg

Pegasys Den Europæiske Union - dansk - EMA (European Medicines Agency)

pegasys

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 og 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. med hensyn til beslutningen om at indlede behandling hos pædiatriske patienter, se afsnit 4. 2, 4. 4 og 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 og 5. for at hepatitis c virus (hcv) genotype specifik aktivitet, se afsnit 4. 2 og 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. når det besluttes at indlede behandling i barndommen, er det vigtigt at overveje, væksthæmning, der er fremkaldt af en kombination terapi. reversibilitet af væksthæmning er usikker. beslutningen om at behandling skal ske på grundlag af en individuel vurdering (se afsnit 4.

Alpheon Den Europæiske Union - dansk - EMA (European Medicines Agency)

alpheon

biopartners gmbh - recombinant human interferon alfa-2a - hepatitis c kronisk - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.

Doleron 500+150 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

doleron 500+150 mg filmovertrukne tabletter

karo pharma ab - ibuprofen, paracetamol - filmovertrukne tabletter - 500+150 mg

Iomeron 150 mg Iod/ml injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

iomeron 150 mg iod/ml injektionsvæske, opløsning

bracco imaging s.p.a. - iomeprol - injektionsvæske, opløsning - 150 mg iod/ml

Remeron Smelt 15 mg smeltetabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

remeron smelt 15 mg smeltetabletter

merck sharp & dohme b.v. - mirtazapin - smeltetabletter - 15 mg

Remeron Smelt 30 mg smeltetabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

remeron smelt 30 mg smeltetabletter

merck sharp & dohme b.v. - mirtazapin - smeltetabletter - 30 mg

Remeron Smelt 45 mg smeltetabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

remeron smelt 45 mg smeltetabletter

merck sharp & dohme b.v. - mirtazapin - smeltetabletter - 45 mg

Iomeron 200 mg Iod/ml injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

iomeron 200 mg iod/ml injektionsvæske, opløsning

bracco imaging s.p.a. - iomeprol - injektionsvæske, opløsning - 200 mg iod/ml